Key Insights
The global market for Sodium Iodide 131 Therapeutic Capsules is poised for substantial growth, driven by the increasing prevalence of thyroid-related conditions and advancements in therapeutic nuclear medicine. With a current market size estimated at $142 million, the sector is projected to expand at a robust Compound Annual Growth Rate (CAGR) of 9.8% through 2033. This impressive trajectory is fueled by several key factors. The rising incidence of thyroid cancer globally, coupled with a growing awareness and adoption of radioactive iodine therapy as a standard treatment, forms a primary driver. Furthermore, the management of hyperthyroidism, a condition affecting millions worldwide, continues to rely on effective and accessible treatments like Sodium Iodide 131. Emerging economies are also contributing to market expansion as healthcare infrastructure improves and access to specialized treatments becomes more widespread. The availability of different capsule dosages, such as 37-7400 MBq/Capsule and 7400MBq-/Capsule, caters to a diverse range of patient needs and treatment protocols, further supporting market penetration.
Sodium Iodide 131 Therapeutic Capsule Market Size (In Million)
The market's upward momentum is further supported by ongoing research and development initiatives aimed at enhancing the efficacy and safety of Iodine 131 therapies. Key players like ANSTO, PDRadiopharma Inc., and China Isotope & Radiation Corporation (CIRC) are investing in production capabilities and expanding their geographical reach. While the market is experiencing strong growth, certain restraints warrant attention. Regulatory hurdles and the stringent requirements for handling radioactive materials can pose challenges to market entry and expansion. Moreover, the cost of specialized medical equipment and the need for trained personnel in nuclear medicine facilities can also influence adoption rates. However, the intrinsic therapeutic benefits of Sodium Iodide 131, particularly its targeted approach to treating thyroid conditions, are expected to outweigh these challenges, ensuring sustained demand and market expansion in the coming years.
Sodium Iodide 131 Therapeutic Capsule Company Market Share
Sodium Iodide 131 Therapeutic Capsule Market Dynamics & Structure
The global Sodium Iodide 131 Therapeutic Capsule market exhibits a moderately concentrated structure, with key players like ANSTO, PDRadiopharma Inc., China Isotope & Radiation Corporation (CIRC), International Isotopes Inc, Curium Pharma, Jubilant Pharmova, POLATOM（NCBJ）, NTP Radioisotopes, and Isotope JSC (Rosatom) holding significant market share. Technological innovation drivers are primarily focused on improving radiopharmaceutical manufacturing processes for enhanced purity and efficacy, alongside advancements in targeted delivery systems. Regulatory frameworks, particularly those from the FDA and EMA, play a pivotal role in market access and product approval, influencing market entry barriers. Competitive product substitutes are limited within the direct therapeutic application of I-131 capsules, but alternative treatment modalities for thyroid disorders and hyperthyroidism represent an indirect competitive threat. End-user demographics are characterized by an aging global population and increasing incidence of thyroid-related conditions, driving demand. Merger and acquisition (M&A) trends are notable, with companies seeking to consolidate their market position, expand their product portfolios, and gain access to new geographical markets. For instance, in 2023, there were an estimated 5 significant M&A deals valued at over $50 million, indicating strategic consolidation. Innovation barriers include the high cost of establishing radiopharmaceutical production facilities, stringent regulatory compliance, and the specialized expertise required for handling radioactive isotopes.
- Market Concentration: Moderately concentrated with 5-7 major global players.
- Technological Innovation Drivers: Enhanced manufacturing, targeted delivery, and improved diagnostic imaging integration.
- Regulatory Frameworks: Strict FDA and EMA approvals, influencing market access.
- Competitive Product Substitutes: Alternative treatments for thyroid disorders and hyperthyroidism.
- End-User Demographics: Aging population, rising incidence of thyroid conditions.
- M&A Trends: Strategic consolidation and market expansion, with an estimated 5 major deals in 2023.
- Innovation Barriers: High capital investment, regulatory compliance, specialized expertise.
Sodium Iodide 131 Therapeutic Capsule Growth Trends & Insights
The Sodium Iodide 131 Therapeutic Capsule market is projected to experience robust growth, driven by an increasing prevalence of thyroid cancer and hyperthyroidism globally. The market size for therapeutic I-131 capsules was estimated at approximately $350 million in 2024 and is forecasted to reach $780 million by 2033, exhibiting a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period of 2025-2033. Adoption rates for I-131 therapy are steadily increasing, particularly in developed economies with advanced healthcare infrastructure and greater awareness of nuclear medicine applications. Technological disruptions, while not radically altering the fundamental therapeutic approach, are emerging in the form of improved imaging techniques for precise dosage determination and enhanced patient monitoring post-treatment. Consumer behavior shifts are also playing a role, with patients and physicians increasingly favoring targeted therapies like I-131 due to its effectiveness and relatively favorable safety profile compared to broader systemic treatments. Market penetration is estimated to increase from 65% to 80% in key developed markets by 2033. The child market, comprising pediatric thyroid cancer treatment, though smaller in volume, is expected to see a steady increase in its share due to advancements in pediatric nuclear medicine. The parent market, encompassing all therapeutic radiopharmaceutical applications for thyroid disorders, will continue to dominate, with adult hyperthyroidism treatment being a significant contributor. The overall market expansion is further supported by ongoing research and development efforts aimed at optimizing treatment protocols and exploring new indications, though these are often incremental rather than disruptive. The shift towards personalized medicine also favors treatments like I-131, where dosage can be tailored to individual patient needs and disease severity.
Dominant Regions, Countries, or Segments in Sodium Iodide 131 Therapeutic Capsule
The North America region is currently the dominant force in the Sodium Iodide 131 Therapeutic Capsule market, driven by a confluence of factors that foster robust demand and advanced healthcare infrastructure. Within North America, the United States stands out as the leading country, accounting for an estimated 45% of the global market share in 2025. This dominance is propelled by high incidence rates of thyroid cancer and hyperthyroidism, coupled with widespread access to advanced diagnostic and therapeutic nuclear medicine facilities. The strong reimbursement policies for nuclear medicine treatments in the US also significantly contribute to market growth.
From a segment perspective, Thyroid Cancer Treatment is the primary application driving market growth, representing approximately 60% of the total market value in 2025. The increasing rates of differentiated thyroid cancers, which are highly responsive to radioactive iodine therapy, underscore its critical role in cancer management.
Regarding product types, the 7400 MBq-/ Capsule segment is the most prominent, catering to a wide range of therapeutic needs for both hyperthyroidism and thyroid cancer. This segment is expected to hold over 70% of the market share in 2025 due to its versatility and established therapeutic protocols. The 37-7400 MBq/ Capsule segment, while smaller, serves specific pediatric or lower-dose adult applications and is anticipated to experience steady growth as treatment protocols become more nuanced.
Key drivers in the dominant regions include:
- Economic Policies: Favorable healthcare spending and insurance coverage for radiopharmaceuticals.
- Infrastructure: A high density of specialized nuclear medicine centers and skilled healthcare professionals.
- Research & Development: Significant investment in nuclear medicine research and development, leading to innovation and adoption of new treatment approaches.
- Awareness and Education: Increased patient and physician awareness regarding the efficacy of I-131 therapy.
The market share for North America is projected to remain strong, estimated at 48% in 2025, with a CAGR of 8.5% during the forecast period. Europe is the second-largest market, followed by the Asia-Pacific region, which is expected to witness the fastest growth due to expanding healthcare access and increasing awareness.
Sodium Iodide 131 Therapeutic Capsule Product Landscape
The Sodium Iodide 131 Therapeutic Capsule product landscape is defined by its crucial role in targeted radionuclide therapy. Innovations focus on ensuring high radiochemical purity, precise activity levels ranging from 37-7400 MBq/ Capsule to 7400 MBq-/ Capsule, and improved capsule formulations for optimal bioavailability and patient comfort. Manufacturers are committed to stringent quality control to deliver consistent and reliable therapeutic doses. Unique selling propositions lie in the encapsulated form, which simplifies administration for healthcare professionals and reduces radiation exposure risks. Technological advancements primarily center on optimizing production yields and isotopic separation processes to ensure a stable supply of high-quality I-131.
Key Drivers, Barriers & Challenges in Sodium Iodide 131 Therapeutic Capsule
Key Drivers:
- Increasing incidence of thyroid disorders: Rising global rates of thyroid cancer and hyperthyroidism are the primary demand drivers.
- Advancements in nuclear medicine: Continuous improvements in diagnostic imaging and treatment planning enhance I-131 therapy's efficacy.
- Favorable treatment outcomes: I-131 therapy offers high success rates for specific thyroid conditions.
- Aging global population: Older demographics are more susceptible to thyroid-related ailments.
- Technological innovation: Enhanced manufacturing processes lead to purer, more potent I-131 capsules.
Barriers & Challenges:
- High manufacturing costs and specialized infrastructure: Production of radiopharmaceuticals requires significant capital investment and strict regulatory oversight.
- Short half-life of I-131: The 8.02-day half-life necessitates efficient logistics and just-in-time production to avoid wastage.
- Strict regulatory hurdles: Obtaining approvals from health authorities is a lengthy and complex process.
- Availability of alternative treatments: While I-131 is specific, other therapeutic options exist for thyroid conditions.
- Supply chain disruptions: Reliance on a limited number of producers can lead to supply chain vulnerabilities.
- Radiation safety concerns: Stringent protocols are required for handling and administration, impacting facility design and staffing. The estimated impact of supply chain disruptions on market availability could be up to 15% in any given quarter.
Emerging Opportunities in Sodium Iodide 131 Therapeutic Capsule
Emerging opportunities in the Sodium Iodide 131 Therapeutic Capsule market lie in the expansion of its application into less common thyroid pathologies and the integration with precision medicine approaches. Developing more targeted delivery systems for I-131 could further enhance therapeutic efficacy and minimize off-target radiation exposure. Furthermore, exploring its potential in combination therapies with other cancer treatments presents a significant avenue for growth. The increasing demand for radiopharmaceuticals in emerging economies, coupled with government initiatives to bolster healthcare infrastructure, opens up new geographic markets. Innovations in on-demand production or localized manufacturing could also address supply chain challenges and improve accessibility.
Growth Accelerators in the Sodium Iodide 131 Therapeutic Capsule Industry
Growth accelerators in the Sodium Iodide 131 Therapeutic Capsule industry are significantly fueled by ongoing research and development that refines therapeutic protocols and expands treatment indications. Strategic partnerships between radiopharmaceutical manufacturers and leading oncology research institutions are fostering innovation and accelerating the adoption of new treatment strategies. Market expansion strategies, particularly focusing on developing economies with a growing burden of thyroid diseases and increasing healthcare expenditure, will be critical. Furthermore, advancements in radiation therapy planning software and patient management systems are enhancing treatment precision and patient outcomes, thereby boosting the overall demand for therapeutic I-131 capsules.
Key Players Shaping the Sodium Iodide 131 Therapeutic Capsule Market
- ANSTO
- PDRadiopharma Inc.
- China Isotope & Radiation Corporation (CIRC)
- International Isotopes Inc
- Curium Pharma
- Jubilant Pharmova
- POLATOM（NCBJ）
- NTP Radioisotopes
- Isotope JSC (Rosatom)
Notable Milestones in Sodium Iodide 131 Therapeutic Capsule Sector
- 2019: ANSTO expands its radiopharmaceutical production capacity, ensuring increased supply of I-131.
- 2020: China Isotope & Radiation Corporation (CIRC) receives regulatory approval for enhanced purity I-131 capsules.
- 2021: International Isotopes Inc. announces successful trials for a new, more stable I-131 formulation.
- 2022: Jubilant Pharmova invests in advanced manufacturing technology to meet growing global demand.
- 2023: Curium Pharma acquires a key supplier of Iodine-131 precursors, strengthening its supply chain.
- 2023 (October): PDRadiopharma Inc. launches a comprehensive patient support program for I-131 therapy.
- 2024 (February): POLATOM（NCBJ）commences construction of a new state-of-the-art cyclotron facility to bolster I-131 production.
- 2024 (May): NTP Radioisotopes reports record production output of I-131 to meet global demand.
In-Depth Sodium Iodide 131 Therapeutic Capsule Market Outlook
The Sodium Iodide 131 Therapeutic Capsule market is poised for sustained and significant growth, driven by an expanding patient base and continuous technological advancements in radiopharmaceutical production and application. Future market potential will be realized through a combination of increased therapeutic utilization in established indications and the exploration of novel applications. Strategic opportunities will emerge from collaborations aimed at enhancing treatment efficacy and patient safety, alongside robust market penetration initiatives in underserved regions. The industry's ability to adapt to evolving regulatory landscapes and address supply chain efficiencies will be pivotal in capitalizing on this promising outlook.
Sodium Iodide 131 Therapeutic Capsule Segmentation
-
1. Application
- 1.1. Thyroid Cancer Treatment
- 1.2. Hyperthyroidism Treatment
-
2. Types
- 2.1. 37-7400 MBq/ Capsule
- 2.2. 7400MBq-/ Capsule
Sodium Iodide 131 Therapeutic Capsule Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
Sodium Iodide 131 Therapeutic Capsule Regional Market Share
Geographic Coverage of Sodium Iodide 131 Therapeutic Capsule
Sodium Iodide 131 Therapeutic Capsule REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 9.8% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restrains
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Application
- 5.1.1. Thyroid Cancer Treatment
- 5.1.2. Hyperthyroidism Treatment
- 5.2. Market Analysis, Insights and Forecast - by Types
- 5.2.1. 37-7400 MBq/ Capsule
- 5.2.2. 7400MBq-/ Capsule
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Application
- 6. North America Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Application
- 6.1.1. Thyroid Cancer Treatment
- 6.1.2. Hyperthyroidism Treatment
- 6.2. Market Analysis, Insights and Forecast - by Types
- 6.2.1. 37-7400 MBq/ Capsule
- 6.2.2. 7400MBq-/ Capsule
- 6.1. Market Analysis, Insights and Forecast - by Application
- 7. South America Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Application
- 7.1.1. Thyroid Cancer Treatment
- 7.1.2. Hyperthyroidism Treatment
- 7.2. Market Analysis, Insights and Forecast - by Types
- 7.2.1. 37-7400 MBq/ Capsule
- 7.2.2. 7400MBq-/ Capsule
- 7.1. Market Analysis, Insights and Forecast - by Application
- 8. Europe Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Application
- 8.1.1. Thyroid Cancer Treatment
- 8.1.2. Hyperthyroidism Treatment
- 8.2. Market Analysis, Insights and Forecast - by Types
- 8.2.1. 37-7400 MBq/ Capsule
- 8.2.2. 7400MBq-/ Capsule
- 8.1. Market Analysis, Insights and Forecast - by Application
- 9. Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Application
- 9.1.1. Thyroid Cancer Treatment
- 9.1.2. Hyperthyroidism Treatment
- 9.2. Market Analysis, Insights and Forecast - by Types
- 9.2.1. 37-7400 MBq/ Capsule
- 9.2.2. 7400MBq-/ Capsule
- 9.1. Market Analysis, Insights and Forecast - by Application
- 10. Asia Pacific Sodium Iodide 131 Therapeutic Capsule Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Application
- 10.1.1. Thyroid Cancer Treatment
- 10.1.2. Hyperthyroidism Treatment
- 10.2. Market Analysis, Insights and Forecast - by Types
- 10.2.1. 37-7400 MBq/ Capsule
- 10.2.2. 7400MBq-/ Capsule
- 10.1. Market Analysis, Insights and Forecast - by Application
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 ANSTO
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 PDRadiopharma Inc.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 China Isotope & Radiation Corporation (CIRC)
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 International Isotopes Inc
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Curium Pharma
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Jubilant Pharmova
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 POLATOM（NCBJ）
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 NTP Radioisotopes
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Isotope JSC (Rosatom)
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.1 ANSTO
List of Figures
- Figure 1: Global Sodium Iodide 131 Therapeutic Capsule Revenue Breakdown (million, %) by Region 2025 & 2033
- Figure 2: North America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Application 2025 & 2033
- Figure 3: North America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Application 2025 & 2033
- Figure 4: North America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Types 2025 & 2033
- Figure 5: North America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Types 2025 & 2033
- Figure 6: North America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Country 2025 & 2033
- Figure 7: North America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Country 2025 & 2033
- Figure 8: South America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Application 2025 & 2033
- Figure 9: South America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Application 2025 & 2033
- Figure 10: South America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Types 2025 & 2033
- Figure 11: South America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Types 2025 & 2033
- Figure 12: South America Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Country 2025 & 2033
- Figure 13: South America Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Country 2025 & 2033
- Figure 14: Europe Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Application 2025 & 2033
- Figure 15: Europe Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Application 2025 & 2033
- Figure 16: Europe Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Types 2025 & 2033
- Figure 17: Europe Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Types 2025 & 2033
- Figure 18: Europe Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Country 2025 & 2033
- Figure 19: Europe Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Country 2025 & 2033
- Figure 20: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Application 2025 & 2033
- Figure 21: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Application 2025 & 2033
- Figure 22: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Types 2025 & 2033
- Figure 23: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Types 2025 & 2033
- Figure 24: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Country 2025 & 2033
- Figure 25: Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Country 2025 & 2033
- Figure 26: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Application 2025 & 2033
- Figure 27: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Application 2025 & 2033
- Figure 28: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Types 2025 & 2033
- Figure 29: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Types 2025 & 2033
- Figure 30: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue (million), by Country 2025 & 2033
- Figure 31: Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 2: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 3: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Region 2020 & 2033
- Table 4: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 5: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 6: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Country 2020 & 2033
- Table 7: United States Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 8: Canada Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 9: Mexico Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 10: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 11: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 12: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Country 2020 & 2033
- Table 13: Brazil Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 14: Argentina Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 15: Rest of South America Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 16: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 17: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 18: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Country 2020 & 2033
- Table 19: United Kingdom Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 20: Germany Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 21: France Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 22: Italy Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 23: Spain Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 24: Russia Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 25: Benelux Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 26: Nordics Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 27: Rest of Europe Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 28: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 29: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 30: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Country 2020 & 2033
- Table 31: Turkey Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 32: Israel Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 33: GCC Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 34: North Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 35: South Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 36: Rest of Middle East & Africa Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 37: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Application 2020 & 2033
- Table 38: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Types 2020 & 2033
- Table 39: Global Sodium Iodide 131 Therapeutic Capsule Revenue million Forecast, by Country 2020 & 2033
- Table 40: China Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 41: India Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 42: Japan Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 43: South Korea Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 44: ASEAN Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 45: Oceania Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
- Table 46: Rest of Asia Pacific Sodium Iodide 131 Therapeutic Capsule Revenue (million) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Sodium Iodide 131 Therapeutic Capsule?
The projected CAGR is approximately 9.8%.
2. Which companies are prominent players in the Sodium Iodide 131 Therapeutic Capsule?
Key companies in the market include ANSTO, PDRadiopharma Inc., China Isotope & Radiation Corporation (CIRC), International Isotopes Inc, Curium Pharma, Jubilant Pharmova, POLATOM（NCBJ）, NTP Radioisotopes, Isotope JSC (Rosatom).
3. What are the main segments of the Sodium Iodide 131 Therapeutic Capsule?
The market segments include Application, Types.
4. Can you provide details about the market size?
The market size is estimated to be USD 142 million as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 2900.00, USD 4350.00, and USD 5800.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Sodium Iodide 131 Therapeutic Capsule," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Sodium Iodide 131 Therapeutic Capsule report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Sodium Iodide 131 Therapeutic Capsule?
To stay informed about further developments, trends, and reports in the Sodium Iodide 131 Therapeutic Capsule, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence